Refocused activities will emphasize high potency, late phase offerings and drug product services3 November 2009
The company presently employs 400 people at its Swiss facilities. The proposed changes would result in the loss of up to 40 positions across the Swiss operations.
The past 18 months has seen some significant changes to the markets CARBOGEN AMCIS serves. While the company has seen a significant increase in the number and rate of progress associated with later phase projects, there has been a substantial decline in the number of early phase projects being generated. “CARBOGEN AMCIS has taken the opportunity to review the business and is making these changes to provide the foundation of a future-oriented business,” said Gaudenz von Capeller, managing director, CARBOGEN AMCIS.
“In the last year, we’ve tried our best to keep all jobs intact,” said von Capeller. “Thus far, due to decisions we’ve made, we’ve been able to weather the economy better than most in our industry. As we make the shift, we will continue to ensure that we meet customer demands and provide the same level of customer service. By making these changes we believe that CARBOGEN AMCIS, continues to be a robust and profitable business and a key part of the Dishman group.”
CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd.,
Source: CARBOGEN AMCIS AG, Bubendorf, Switzerland